[go: up one dir, main page]

CY1108069T1 - Φαρμακευτικη συνθεση σε μορφη υδρογελης για διαδερμικη χορηγηση δραστικων ουσιων - Google Patents

Φαρμακευτικη συνθεση σε μορφη υδρογελης για διαδερμικη χορηγηση δραστικων ουσιων

Info

Publication number
CY1108069T1
CY1108069T1 CY20081100503T CY081100503T CY1108069T1 CY 1108069 T1 CY1108069 T1 CY 1108069T1 CY 20081100503 T CY20081100503 T CY 20081100503T CY 081100503 T CY081100503 T CY 081100503T CY 1108069 T1 CY1108069 T1 CY 1108069T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
hydrogel
active substances
hydrogel form
relates
Prior art date
Application number
CY20081100503T
Other languages
English (en)
Inventor
Patrick Franke
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33395772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108069(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of CY1108069T1 publication Critical patent/CY1108069T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Η εφεύρεση αναφέρεται σε φαρμακευτική σύνθεση σε μορφή υδρογέλης που περιλαμβάνει διεστέρα ανθρακικού οξέος, C2-C4 αλκυλαλκοόλη, δραστική ουσία και μήτρα πολυμερούς. Η εφεύρεση αναφέρεται περαιτέρω στη χρήση διεστέρα ανθρακικού οξέος ως μέσο διαδερμικής διαπέρασης για δραστική ουσία σε φαρμακευτική σύνθεση στη μορφή υδρογέλης, όπου η σύνθεση περιλαμβάνει μήτρα πολυμερούς και C2-C4 αλκυλαλκοόλη. Η εφεύρεση αναφέρεται επίσης σε σύνθεση σταθερή έναντι εφίδρωσης σε μορφή υδρογέλης, η οποία περιλαμβάνει ακρυλικό πολυμερές σε συνδυασμό με παράγωγο κυτταρίνης.
CY20081100503T 2003-04-28 2008-05-13 Φαρμακευτικη συνθεση σε μορφη υδρογελης για διαδερμικη χορηγηση δραστικων ουσιων CY1108069T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03008856 2003-04-28
EP04728563A EP1617827B1 (de) 2003-04-28 2004-04-21 Pharmazeutische zusammensetzung in form eines hydrogels zur transdermalen verabreichung von wirkstoffen

Publications (1)

Publication Number Publication Date
CY1108069T1 true CY1108069T1 (el) 2014-02-12

Family

ID=33395772

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100503T CY1108069T1 (el) 2003-04-28 2008-05-13 Φαρμακευτικη συνθεση σε μορφη υδρογελης για διαδερμικη χορηγηση δραστικων ουσιων

Country Status (32)

Country Link
EP (2) EP1875905B1 (el)
JP (2) JP4829102B2 (el)
KR (1) KR101093999B1 (el)
CN (1) CN1780610B (el)
AR (1) AR044113A1 (el)
AT (2) ATE467412T1 (el)
AU (1) AU2004233572B2 (el)
BR (1) BRPI0409918A (el)
CA (1) CA2523734C (el)
CL (1) CL2004000884A1 (el)
CO (1) CO5640075A2 (el)
CR (1) CR8059A (el)
CY (1) CY1108069T1 (el)
DE (2) DE502004006196D1 (el)
DK (1) DK1617827T3 (el)
EA (1) EA008686B1 (el)
EC (1) ECSP056186A (el)
ES (2) ES2345458T3 (el)
HR (1) HRP20080178T3 (el)
JO (1) JO2492B1 (el)
MX (1) MXPA05011541A (el)
NO (1) NO20055601L (el)
NZ (2) NZ543264A (el)
PE (1) PE20050461A1 (el)
PL (1) PL1617827T3 (el)
PT (1) PT1617827E (el)
RS (1) RS51307B (el)
SI (1) SI1617827T1 (el)
TW (1) TWI343259B (el)
UA (1) UA83036C2 (el)
WO (1) WO2004096191A1 (el)
ZA (1) ZA200509549B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506139D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
GB0506141D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A topical compostion and its uses
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
DE102005035879A1 (de) * 2005-07-30 2007-02-01 Paul Hartmann Ag Hydrogel
SE536091C2 (sv) * 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
JP5934781B2 (ja) * 2011-04-25 2016-06-15 パーク、ジュン−ヒョン 脱毛防止及び発毛促進用外用剤組成物
FR2976808B1 (fr) * 2011-06-22 2013-06-28 Urgo Lab Composition filmogene et son utilisation pour le traitement de l'herpes
US9855211B2 (en) * 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
DE102018213754A1 (de) * 2018-08-15 2020-02-20 Henkel Ag & Co. Kgaa "Tris(hydroxymethyl-)aminomethan oder seine Salze als Wirkstoff zur Reduzierung der Schweißsekretion“

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1182229B (de) 1960-11-16 1964-11-26 Upjohn Co Verfahren zur Herstellung von 7-Methylsteroiden
US3341557A (en) 1961-06-05 1967-09-12 Upjohn Co 7-methyltestosterones
US3924004A (en) 1971-11-24 1975-12-02 Syntex Corp Fatty alcohol-propylene carbonate-glycol solvent cream vehicle
US4000273A (en) 1973-11-01 1976-12-28 Richardson-Merrell Inc. Method for the control of fertility
JPS5540604A (en) * 1978-09-14 1980-03-22 Mitsui Toatsu Chem Inc Improved local topicum
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
JPS5970612A (ja) 1982-10-13 1984-04-21 Nippon Redarii Kk ゲル軟膏基剤
JPH01503281A (ja) * 1987-05-27 1989-11-09 ブルグハルト，クルト 経皮治療に有効な医薬包帯剤およびこれを施用するためのデバイス
EP0394429B1 (de) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend gestoden
WO1993025168A1 (en) * 1992-06-11 1993-12-23 Theratech, Inc. The use of glycerin in moderating transdermal drug delivery
US5460620A (en) * 1992-07-31 1995-10-24 Creative Products Resource, Inc. Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent
AU3723695A (en) 1994-09-14 1996-03-29 Minnesota Mining And Manufacturing Company Transdermal device for delivery of levonorgestrel
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
JPH09194396A (ja) 1996-01-17 1997-07-29 Pola Chem Ind Inc 貼付剤用マトリックス
US5733565A (en) 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
US5736128A (en) * 1996-05-14 1998-04-07 Isp Investments Inc. Cosmetic composition for rejuvenation of skin without skin irritation
AU3136897A (en) 1996-05-22 1997-12-09 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5993787A (en) 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US6767902B2 (en) 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
US20020012694A1 (en) 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
WO1999067271A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Testosterone derivative
FR2781666B1 (fr) * 1998-07-30 2000-09-08 Oreal Composition cosmetique solide et ses utilisations
JP2935113B1 (ja) * 1998-09-24 1999-08-16 小林製薬株式会社 インドメタシン経皮吸収剤
JP2000264899A (ja) * 1999-01-13 2000-09-26 Taisho Pharmaceut Co Ltd ステロイド外用剤
AU2003600A (en) 1999-01-13 2000-08-01 Taisho Pharmaceutical Co., Ltd. External steroid preparation
JP2001139451A (ja) * 1999-11-17 2001-05-22 Lion Corp ジェル状化粧料
CN1481388A (zh) 2000-12-15 2004-03-10 ��˹��ŵ�� 具有雄激素-孕激素混合活性的14(15)-不饱和的15-和/或16-取代的雄激素类
DE10104327A1 (de) * 2001-01-24 2002-07-25 Schering Ag 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate
DE10107663B4 (de) 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung

Also Published As

Publication number Publication date
ES2345458T3 (es) 2010-09-23
EA200501583A1 (ru) 2006-06-30
DK1617827T3 (da) 2008-06-02
JP2010241824A (ja) 2010-10-28
RS51307B (sr) 2010-12-31
WO2004096191A1 (de) 2004-11-11
AU2004233572B2 (en) 2010-07-15
JP4829102B2 (ja) 2011-12-07
AU2004233572A1 (en) 2004-11-11
NZ543264A (en) 2010-03-26
DE502004011164D1 (de) 2010-06-24
MXPA05011541A (es) 2006-05-31
CN1780610B (zh) 2010-06-09
NO20055601D0 (no) 2005-11-25
EP1617827A1 (de) 2006-01-25
ATE467412T1 (de) 2010-05-15
PL1617827T3 (pl) 2008-07-31
NO20055601L (no) 2006-01-26
EA008686B1 (ru) 2007-06-29
CL2004000884A1 (es) 2005-03-11
KR101093999B1 (ko) 2011-12-15
BRPI0409918A (pt) 2006-04-25
TW200524644A (en) 2005-08-01
EP1875905A2 (de) 2008-01-09
CO5640075A2 (es) 2006-05-31
ZA200509549B (en) 2007-02-28
NZ583760A (en) 2011-10-28
EP1875905B1 (de) 2010-05-12
ES2300763T3 (es) 2008-06-16
SI1617827T1 (sl) 2008-06-30
JO2492B1 (en) 2009-10-05
DE502004006196D1 (de) 2008-03-27
CR8059A (es) 2006-05-29
CA2523734C (en) 2009-12-22
CN1780610A (zh) 2006-05-31
AR044113A1 (es) 2005-08-24
ATE385786T1 (de) 2008-03-15
EP1617827B1 (de) 2008-02-13
PT1617827E (pt) 2008-04-30
RS20050809A (sr) 2007-09-21
PE20050461A1 (es) 2005-08-13
UA83036C2 (ru) 2008-06-10
TWI343259B (en) 2011-06-11
CA2523734A1 (en) 2004-11-11
ECSP056186A (es) 2006-04-19
HRP20080178T3 (hr) 2008-05-31
EP1875905A3 (de) 2008-06-25
JP2006524653A (ja) 2006-11-02
KR20060007403A (ko) 2006-01-24
HK1087633A1 (zh) 2006-10-20

Similar Documents

Publication Publication Date Title
CY1108069T1 (el) Φαρμακευτικη συνθεση σε μορφη υδρογελης για διαδερμικη χορηγηση δραστικων ουσιων
KR102219776B1 (ko) 생체 광자성 조성물들, 키트들 및 방법들
ATE499090T1 (de) Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan
CL2010001279A1 (es) Forma de dosificacion que comprende 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato, un vehiculo lipidico, un espesante y un agente de deslizamiento/solubilizante, de grupos definidos.
BRPI0915300B8 (pt) compostos de éster boronato e composições farmacêuticas dos mesmos
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
UY27641A1 (es) Composiciones farmacéuticas de dispersiones amorfas de fármacos y materiales que forman microfases lipófilas
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CY1107446T1 (el) Ανθελμινθικες συνθεσεις
BRPI0606112B8 (pt) 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos
CY1116111T1 (el) Τοπικη συνθεση για τη θεραπεια της ακτινικης κερατωσης
CY1113575T1 (el) Χρηση συνθεσεων οπιοειδων σε συσκευες χορηγησης δραστικης ουσιας χωρις βελονα
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
CY1114653T1 (el) Επιθεμα εμποτισμενο με φαρμακα
DE602004014964D1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)
UY28283A1 (es) Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas
FR2938766B1 (fr) Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat de feuille de vigne (vitis vinifera l.) en tant que principe actif activateur de l'aconitase et protecteur des mitochondries
CU23523B7 (es) Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas
EA200800150A1 (ru) Состав с пролонгированным высвобождением действующих начал лекарственного средства
AR029718A1 (es) Composicion farmaceutica a base de cocaetileno y su utilizacion para el tratamiento de la dependencia de las substancias psicoactivas
EA200701741A1 (ru) Композиция, содержащая окаперидон